MusclePharm Corporation MSLP OTC

MusclePharm Corporation (MSLP) generated $-3.58M in operating cash flow for quarter ending 2022-03-31. After capital expenditures of $0.00, free cash flow was $-3.58M.

Free cash flow margin was -27.3% of revenue. Cash conversion ratio was 0.57x, suggesting some earnings are non-cash.

Criteria supported by this page:

• HEALTH (0/100, Fail) — weak cash flow raises concerns about debt servicing
• MOAT (7/100, Fail) — limited free cash flow weakens the competitive position
• INCOME (10/100) — Cash conversion ratio was 0.57x suggests some earnings are non-cash items

Overall SharesGrow Score: 11/100 with 0/7 criteria passed.